Illustration of targeted therapy for Adult-Onset Still's Disease

AOSD Breakthrough: Can Combining Therapies Conquer Still's Disease?

Theo Raines monogram
Theo Raines in Health & Wellness October 2026 • 4 min read.

"New research suggests that Janus kinase inhibitors combined with existing treatments may offer hope for patients with refractory adult-onset Still's disease."


Adult-onset Still's disease (AOSD) presents a significant challenge to both patients and physicians. This rare systemic inflammatory disorder of unknown origin manifests with a constellation of symptoms, including high fevers, joint pain, rash, and internal organ involvement. Diagnosing AOSD is often a process of exclusion, requiring the ruling out of infections, autoimmune disorders, and malignancies.

Traditional treatments for AOSD range from non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids to immunosuppressants and biologics targeting specific cytokines like IL-1 and IL-6. While these therapies can be effective in managing symptoms, some patients develop resistance or dependence on high doses of corticosteroids, leading to significant side effects and a diminished quality of life.

A recent case study published in 'Rheumatology' explores a novel therapeutic approach for refractory AOSD. The study investigates the use of Janus kinase (JAK) inhibitors, specifically baricitinib, in combination with anakinra, an IL-1 inhibitor, to treat a patient who had previously shown resistance to multiple conventional therapies. This article delves into the details of this case, examining the potential of JAK inhibitors to revolutionize the treatment of AOSD and offer new hope to patients struggling with this challenging condition.

AI Search Multiple angles on this topic

Prevalence and Disease Burden

Adult-onset Still disease (AOSD) is an idiopathic autoinflammatory disorder associated with fever, arthralgia, and an evanescent salmon-pink maculopapular rash. One review estimates global prevalence at approximately 1–7 per 100,000 people and reports slightly more frequent occurrence in women, with peaks at ages 16–25 and 36–46. Another source gives a global incidence of 0.16–0.40 per 100,000 and estimated prevalence of 1–34 per 1,000,000, so the prevalence estimates differ across sources. A 2025 single-center review snippet reports macrophage activation syndrome in 15% of patients and describes it as the most severe complication.

Evolving Understanding of AOSD

AOSD has been described as an idiopathic systemic inflammatory disease whose cause is not fully understood. More recent characterizations describe it as a rare, polygenic systemic autoinflammatory disorder arising from complex interactions between genetic and environmental factors. A 2024 review highlights macrophage activation and its resulting T helper 1 (Th1) response as central to pathogenesis, while noting that the underlying mechanisms are not completely recognized.

The Case: A Treatment Journey with Refractory AOSD

Illustration of targeted therapy for Adult-Onset Still's Disease

The patient, a 43-year-old woman with no significant prior medical history, was initially admitted to the hospital with a sudden onset of high fever (40°C), urticaria, arthritis, odynophagia, and dyspnea. Initial blood tests revealed elevated levels of C-reactive protein (CRP) and ferritin, indicative of significant inflammation. Further investigation, including a PET scan and biopsy of a mediastinal nodule, ruled out other potential causes, leading to a diagnosis of AOSD.

Over the years, the patient underwent various treatments, including corticosteroids, hydroxychloroquine, methotrexate, sulfasalazine, and ciclosporin. While some treatments provided temporary relief, the patient eventually developed resistance or experienced intolerable side effects. Biologic therapies such as anakinra, infliximab, tocilizumab, and abatacept were also tried, but none provided sustained benefit.

  • Initial Presentation (July 2010): High fever, urticaria, arthritis, odynophagia, and dyspnea.
  • Diagnosis: Adult-Onset Still’s Disease (AOSD) after excluding infections, autoimmune disorders, and malignancies.
  • Treatment History:
    • Corticosteroids (prednisone)
    • Hydroxychloroquine, methotrexate, and sulfasalazine (discontinued due to side effects)
    • Ciclosporin (temporary control, then relapse)
    • Anakinra (initial success, then relapse)
    • Infliximab (severe hypersensitivity reaction)
    • Tocilizumab and abatacept (no significant benefit)
  • May 2015: Anakinra re-attempted with methylprednisolone (16 mg/day) - stabilized but no remission.
  • December 2017: Baricitinib (4 mg/day) added to anakinra regimen.
AI Search Multiple angles on this topic

A Polygenic Autoinflammatory Classification

A review of AOSD treatment describes the disease as a rare inflammatory disorder that has been classified as a polygenic autoinflammatory disorder. This classification provides a framework for understanding AOSD as an inflammatory condition with a complex basis. The source snippet does not provide specific newer treatment findings or comparative outcomes.

Variable Course and Diagnostic Challenges

AOSD can follow a monocyclic, polycyclic, or chronic course, with systemic or articular symptoms predominating. Reviews identify diagnostic difficulty and limited therapeutic options as challenges in management. Mayo Clinic notes that no single test can diagnose adult Still disease; diagnosis draws on symptoms, while imaging may show joint or organ injury and blood tests may reveal elevated inflammatory markers such as CRP and ESR.

Treatment Goals

A 2018 comprehensive review describes AOSD treatment strategy as targeting pro-inflammatory signs and symptoms. It also identifies preventing organ damage and life-threatening complications, while minimizing treatment adverse effects, as key goals. The supplied source does not compare specific therapies or report comparative effectiveness.

Due to persistent joint involvement and signs resembling rheumatoid arthritis (RA), baricitinib, a JAK inhibitor, was added to the patient's treatment regimen in December 2017. Impressively, the patient's condition improved significantly, and corticosteroids were successfully withdrawn within a month. After nine months of baricitinib treatment, the patient achieved remission, and the dosage of anakinra was gradually reduced. This outcome suggests the potential of JAK inhibitors in managing refractory AOSD, particularly in patients with prominent joint involvement.

JAK Inhibitors: A Promising New Avenue for AOSD Treatment

This case study offers a promising glimpse into the potential of JAK inhibitors, such as baricitinib, in the treatment of refractory AOSD. By targeting multiple cytokines involved in the inflammatory cascade, JAK inhibitors may offer a more comprehensive approach to managing the disease compared to traditional therapies that focus on individual cytokines. While further research is needed to fully elucidate the role of JAK inhibitors in AOSD and to assess their long-term safety and efficacy, this case provides a compelling rationale for exploring their use in patients who have failed to respond to conventional treatments.

AI Search Multiple angles on this topic

Building Treatment Consensus

A 2023 study sought expert consensus on diagnostic and treatment strategies for AOSD through a Delphi panel. Its source reports that there is no internationally accepted treatment guideline and that most doctors treating AOSD in the Netherlands see fewer than five patients per year. A 2021 review describes AOSD’s hallmark as a cytokine storm triggered by dysregulated inflammation and focuses on current and emerging biological therapy, but the supplied snippet does not identify particular therapies or outcomes.

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is Adult-onset Still's disease (AOSD)?

Adult-onset Still's disease (AOSD) is a rare inflammatory condition that presents with symptoms such as high fevers, joint pain, rash, and possible internal organ involvement. It is considered a systemic inflammatory disorder of unknown origin. Diagnosing AOSD can be challenging, as it often involves ruling out other conditions like infections, autoimmune disorders, and malignancies. The case study highlights the challenges faced by patients and physicians in managing this condition, particularly when it becomes refractory to traditional treatments.

2

What are the traditional treatments for Adult-onset Still's disease (AOSD)?

Traditional treatments for Adult-onset Still's disease (AOSD) include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, immunosuppressants, and biologics targeting specific cytokines, such as IL-1 and IL-6. While these treatments can manage symptoms, some patients develop resistance or experience side effects. The case study specifically mentions treatments such as corticosteroids (prednisone), hydroxychloroquine, methotrexate, sulfasalazine, ciclosporin, anakinra, infliximab, tocilizumab, and abatacept, demonstrating the variety of therapies used and the potential for resistance.

3

What are Janus kinase (JAK) inhibitors and how do they relate to Adult-onset Still's disease (AOSD)?

Janus kinase (JAK) inhibitors, like baricitinib, are a newer class of drugs that target multiple cytokines involved in the inflammatory cascade. In the context of Adult-onset Still's disease (AOSD), this approach may offer a more comprehensive treatment compared to therapies that target individual cytokines. The case study shows that adding baricitinib to an anakinra regimen led to significant improvement in a patient who had previously shown resistance to multiple conventional treatments. This suggests that JAK inhibitors can be effective in managing refractory AOSD, especially in cases with significant joint involvement, potentially revolutionizing the treatment approach.

4

What does it mean for Adult-onset Still's disease (AOSD) to be considered 'refractory'?

Refractory Adult-onset Still's disease (AOSD) refers to cases where the disease does not respond adequately to standard treatments or when the patient experiences intolerable side effects. In the described case, the patient had failed to respond to multiple conventional therapies including corticosteroids, hydroxychloroquine, methotrexate, sulfasalazine, ciclosporin, and several biologics. This resistance to treatment highlights the challenges in managing AOSD and underscores the need for alternative therapeutic approaches. The successful use of baricitinib in this case offers new hope for patients who have not found relief with existing treatments.

5

What is the significance of the case study involving Adult-onset Still's disease (AOSD) and the combination of therapies?

The case study's significance lies in its demonstration of a novel therapeutic approach for refractory Adult-onset Still's disease (AOSD). By combining a Janus kinase (JAK) inhibitor, baricitinib, with an IL-1 inhibitor, anakinra, the patient experienced significant improvement and achieved remission after failing multiple other treatments. This outcome suggests that combining JAK inhibitors with existing treatments could offer new hope for patients struggling with this challenging condition. The success of this combination highlights the potential for JAK inhibitors to manage refractory AOSD, particularly in patients with prominent joint involvement and offers a rationale for exploring their use in those who have not responded to conventional treatments.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.